Japanese drugmaker Eisai is cutting its R&D operations, with plans to eliminate 130 positions from its facility in Andover, MA, as well as other research centers around the world.
Eisai announced late last week that it is bringing the ax down on its R&D facility in Andover, MA, and other research centers around the globe as it chops 130 staffers out of its operations.
Eisai gave Arena Pharmaceuticals' obesity drug Belviq another vote of confidence. The Japanese drugmaker, already marketing the drug in the U.S., signed up to promote it in most other global markets, too. And it gave Arena a $60 million up-front payment to seal the deal.
Japan's Eisai is slashing 20 R&D jobs and eliminating some 30 consultants contracts in the UK as part of a global R&D restructuring, according to a local spokesperson for the company.
Japan's Eisai, which lashed out this week at the U.K.'s cost watchdog as too restrictive, has lost its bid to force the DEA to schedule Fycompa so it can get it launched in the U.S. The seizure drug was approved by the FDA a year ago.
Plenty of drugmakers have grumbled about the U.K.'s cost-effectiveness gatekeepers. The National Institute for Health and Care Excellence does routinely reject new drugs, particularly unless--and until--their makers offer price breaks. But until now, no major drugmaker has threatened to stop investing in Britain unless NICE changes its game.
Analysts promised a battle of obesity drugs between Arena's Belviq and Vivus' Qsymia. But in marketing partner Eisai, Arena has a weapon Vivus lacks--and that weapon is about to get bigger. The Japanese company plans to add more than 200 sales reps to its army by December, doubling its size since the drug hit the market this June.
Japanese drugmaker Eisai said a site in the U.K. has won approval from the FDA to manufacture its new epilepsy drug, which the FDA approved nearly a year ago. Now it just needs the Drug Enforcement Agency to quit sitting on it so it can get to market with Fycompa, a potential blockbuster.
Eisai has had it with the Drug Enforcement Administration. The Japanese drugmaker won FDA approval for its new seizure drug, Fycompa, last October. But the DEA still hasn't done its part by classifying it as a controlled substance--and that means the drug can't launch.
Last October, when the FDA handed down an approval for its new epilepsy drug Fycompa, the Japanese pharma company Eisai had hopes of moving fast to roll out a blockbuster marketing campaign. But an unfunny thing happened on the way to the marketplace: The DEA has yet to complete the classification process--7 months after Eisai filed with the agency.